CMPX

0.65972.77%
BG

Bing Gong

Chief Scientific Officer

Mr. Bing Gong, Ph.D., is Chief Scientific Officer of Compass Therapeutics, Inc. since 2026 and served as Senior Vice President of Discovery Research from August 2024 until 2026. He bringing more than 10 years of biotech industry experience as a scientific leader for protein analytics and characterization. Before joining Compass, he was a Senior Principal Scientist at Pfizer Global BioTherapeutic Technologies, where he focused on developability assessment of antibody therapeutics. Earlier at his career, he worked at GlycoFi, a wholly owned subsidiary of Merck, where he led a team of scientists responsible for biochemical and biophysical characterization of therapeutic proteins. Dr. Gong has published extensively on glycoprotein analysis and therapeutic antibody development and characterization. He earned his PhD in biochemical engineering from the Thayer School of Engineering at Dartmouth College on a Merck Research Laboratories sponsored Doctoral Fellowship. He has an MSc in biochemistry from UMass-Amherst and a BSc in Microbiology from Huazhong Agricultural University in China.

Positions